MONTREAL, Jan. 9 /PRNewswire/ - Chronogen Inc. (Montreal, Canada), a biopharmaceutical company developing novel therapeutics to treat oxidative stress and lipid disorders in age-related diseases announced today that it has strengthened its management by appointing Dr. Jean-Marie Houle as Vice- President of Research and Development. Dr. Houle brings an exceptional reputation based on more than 20 years of experience. In this role, he will oversee the company's pre-clinical and clinical development aspects.
"We are extremely pleased to have Dr. Houle in our team. His wealth of knowledge and proven abilities in research & development will truly be a valuable asset to the company as we move forward in our programs in both preclinical and clinical phases," said Max Fehlmann, Chief Executive Officer of Chronogen.
Dr.Houle is a pharmacy graduate of Universite de Montreal where he also obtained his M.Sc. and Ph.D. in Pharmaceutical Sciences. From 1987, Dr Houle's leadership in drug development enabled him to occupy key positions for biopharmaceutical/contract research organizations. In 1994, he became Scientific Director in a fast-growing CRO, LAB Pharmacological Research Intl, where he supervised the core of scientists and project managers responsible for Phase I-III projects in all major therapeutic areas. In 1998, he joined the biopharmaceutical company QLT for which he led the PK/Clinical Pharmacology aspects of the company's programs and advanced several compounds from pre-clinical concepts up to Phase II. He played an important role in the successful regulatory approval of Visudyne(R) in US, Canada, Europe and Japan. Then as a consultant over the last 18 months, he was also involved in various therapeutic areas from pre-clinical lead optimization to NDA submission and FDA Advisory Panel.
"We believe that Dr. Houle's experience will allow us to accelerate the execution of our business plan and help us accomplish and overpass our clinical milestones." said Max Fehlmann.
Chronogen Inc., a privately-owned biopharmaceutical company, is a leader in the identification of drug targets that control molecular pathways underlying age-related diseases. Chronogen has developed unique, rapid, and reliable in vivo assays that have been successfully used to identify small- molecules drugs that can modulate the disease determinants such as reactive oxygen species and lipoprotein levels. The mission of Chronogen is to develop innovative small-molecule drugs to treat oxidative stress and lipid disorders in age-related diseases including neurological and cardiovascular diseases.
More information on Chronogen Inc. can be found on: http://www.chronogen.com
CONTACT: please contact: Pascal Puchois, Ph.D., VP Corporate & BusinessDevelopment, (514) 521-9595 ext. 201, Fax: (514) 521-9087,firstname.lastname@example.org